Bird flu can live in raw milk for more than a week, study finds
The bird flu virus can remain infectious in raw milk for over a day at room temperature and more than a week when refrigerated, according to a new, non-peer-reviewed research from a group of UK scientists.
The study, published in medRxiv, examined the stability of the H5N1 avian influenza virus in raw cow and sheep milk, with researchers simulating storage conditions common in dairy settings.
'High viral titres were detected in milk from infected cows, raising concerns about onwards human infections,' the authors wrote.
Scientists emphasized that pasteurization effectively kills the virus, but unpasteurized milk poses a potential risk of infection, both through occupational exposure in dairies and the consumption of raw milk.
To test how long the virus remains infectious, scientists incubated the virus in pasteurized milk at room temperature and at 39.2 F, simulating both ambient dairy conditions and refrigerated storage. They also tested sheep's milk using a lab strain of avian flu.
Scientists stressed that these results represent a 'worst-case scenario' and are meant to provide an 'upper-bound' estimate of how long H5N1 might survive in milk. They urged continued precautions to reduce zoonotic transmission risks.
Bird flu has devastated poultry and dairy farms, and sent the price of eggs soaring in the U.S. since it was first detected in North America in late 2021.
More than 12,000 individual birds have tested positive since the virus began spreading, according to the Agriculture Department.
The Associated Press contributed to this report.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Why Oscar Health, Inc. (OSCR) Soared On Thursday
We recently published a list of . In this article, we are going to take a look at where Oscar Health, Inc. (NYSE:OSCR) stands against other best-performing stocks on Thursday. Oscar Health snapped a five-day losing streak on Thursday, jumping 10.6 percent to close at $15.65 apiece as investors resorted to bargain-hunting while waiting for more concrete developments on the Trump administration's Medicare Advantage review. Earlier this year, lawmakers passed a $5-trillion tax-and-spending package that shaves as much as $900 billion in Medicaid, which servers over 70 million low-income households. A close up of a patient and a healthcare professional engaging in conversation, showing the company's commitment to patient care. Now, Senate Republicans to broaden savings by looking for supposed inefficiencies in the Medicare program for senior citizens. In the first quarter of the year, Oscar Health, Inc. (NYSE:OSCR) registered a 55-percent increase in attributable net income of $275 million versus the $177 million registered in the same period last year. Revenues rose by 42 percent to $3.046 billion from $2.142 billion year-on-year. Overall, OSCR ranks 5th on our list of best-performing stocks on Thursday. While we acknowledge the potential of OSCR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 hours ago
- Yahoo
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating
Matthew Caufield, an analyst from H.C. Wainwright, initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) with a Buy rating and a $8 price target, on June 4. The analyst gave the optimistic rating due to the company's VAFSEO product and its potential in the CKD anemia market. VAFSEO is an approved treatment for anemia in adults with chronic kidney disease on dialysis. According to the analyst, the treatment is gaining considerable momentum among dialysis organizations, and this trend is anticipated to support near-term growth. He expects VAFSEO's ongoing launch to offset the effect of generics on AURYXIA, another product by Akebia Therapeutics, Inc. (NASDAQ:AKBA) that deals with hyperphosphatemia. A biopharmaceutical team in a laboratory analyzing new compounds to develop therapeutics. The analyst also reasoned that Akebia Therapeutics, Inc. (NASDAQ:AKBA) is positioned for success as it has secured contracts that cover almost all dialysis patients in the US. VAFSEO offers flexibility in its dosing regimen, ranging from 150mg to 600mg, making it a factor that allows for personalized treatment and potentially growing prescriptions. Caufield pointed out VAFSEO's oral administration as another reason supporting the optimistic rating, giving it an advantage over existing therapies, such as iron supplementation and erythropoiesis-stimulating agents. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company that develops and commercializes drugs to treat metabolic and renal diseases. While we acknowledge the potential of AKBA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
18 hours ago
- Yahoo
Migratory birds develop antibodies to bird flu, officials say
(WAVY) – Wildlife officials are keeping a close eye on the spread of avian influenza after along the North Carolina coast earlier this year — most of them brown pelicans. The outbreak has since been linked to the H5N1 strain of bird flu, a virus that continues to mutate and occasionally jump to other species, raising concern among experts. Miranda Turner, a wildlife health biologist with the North Carolina Wildlife Resources Commission, said the area is a prime wintering ground for birds — making it easier for disease to spread. 'When you bring a lot of animals together and you have them traveling from different locations, it's a really good way to transmit diseases,' Turner said. In Hampton Roads, bird flu outbreaks aren't new. Lisa Barlow, president of T recalls treating sick and dying Canada geese during a 2021 outbreak on the Lafayette River. 'We dealt with about three to four dozen Canada geese that came in sick and dying,' Barlow said. 'Only six survived the flu, and even those had to be euthanized due to severe neurological symptoms.' Barlow described birds arriving unable to hold their heads up, their beaks caked in mud. Many died within 24 hours. As the virus continues to affect wildlife, it's not just birds at risk. , including seals, cats and even cattle. Experts say it's mutated at least several times since it was first identified. 'I mean, anything that can do that — it's kind of frightening, but amazing,' Barlow said. Despite the concerning spread, health officials emphasize the risk to humans remains low. According to the Centers for Disease Control and Prevention, 70 human cases have been reported nationwide, including one death. Most infections have been among people with repeated exposure to infected animals, such as poultry or dairy farm workers. 'There's really low risk,' Turner said. 'Still, it's a good idea to clean bird feeders regularly and wear gloves or a mask if you handle injured wildlife.' Barlow also urges caution for those who come across sick birds. 'If you do want to help, wear gloves, protect yourself,' she said. 'Common sense goes a long way.' Meanwhile, as migratory birds continue to interact and spread the virus, some are developing natural antibodies, according to Turner. 'They're bouncing back and creating herd immunity,' she said. Last week, the Associated Press reported the in funding meant to support Moderna's development of a bird flu vaccine. The vaccine, which uses mRNA technology similar to the COVID-19 vaccine, had shown early promise in clinical trials. For now, wildlife officials say they expect to see more outbreaks in the years ahead, especially during peak migration periods. 'Because this virus is so common in migratory birds, it is likely that we will continue to see cases here and there every winter,' Turner said. As of right now, there have been no confirmed human cases of H5N1 in Virginia and although the risk remains low for humans, for birds it can be extremely deadly – leading to large die-off events like the ones we saw near Cape Hatteras. 'Unfortunately, this was the first kind of major large scale mortality event… while it looks really bad at that small scale of seeing 300 brown pelicans die – it's not impacting their population as a whole or the species as a whole,' adds Turner. Turner also explains that the surviving pelicans are still there, 'The brown pelicans that did survive that event were still nesting on that island successfully and are doing well. So really, it's a short scale kind of scary looking event, but nothing that raises alarm for biologists in the long term.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
